NovoCure Limited IPO Research Information

NovoCure Limited IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on NovoCure Limited, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
NovoCure Limited	NVCR - NASDAQ	$26.00-$29.00	$22.00	$20.16	7.5 million	10/2/2015
Underwriter(s): J.P. Morgan, Deutsche Bank Securities, Evercore ISI
Co-Manager(s): Wells Fargo Securities, JMP Securities, Wedbush PacGrow
Industry: Health Care
Filing(s): Filed 2015-08-31 Terms Added 2015-09-21 Amended Terms 2015-10-01

NovoCure Limited Quote & Chart - Click for current quote - NVCR

About NovoCure Limited (adapted from NovoCure Limited prospectus):
They are a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "NVCR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.